rAAV-Olig001-ASPA

Gene therapy

MMyrtelle Inc.

rAAV-Olig001-ASPA is one of 3 small molecule programs targeting Canavan disease. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Canavan DiseaseActive, not recruiting

Canavan DiseasePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Canavan Disease

#DrugCompanyPhaseTrials

Keppra

UCB

Phase 1

1 2

Rayos

RRoxane Laboratories

Phase 1

1 3

rAAV-Olig001-ASPA

MMyrtelle Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Canavan disease1 trial

rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease

Enrolling by invitation·MMyrtelle Inc.·Phase 1/2·NCT04833907·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for rAAV-Olig001-ASPA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rAAV-Olig001-ASPA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rAAV-Olig001-ASPA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Myrtelle Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Company: MMyrtelle Inc.

rAAV-Olig001-ASPA

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Canavan disease1 trial

References

Drug Info

Quick Facts

Related News